scholarly journals Associations of active commuting with body fat and visceral adipose tissue: A cross-sectional population based study in the UK

2018 ◽  
Vol 106 ◽  
pp. 86-93 ◽  
Author(s):  
Oliver T. Mytton ◽  
David Ogilvie ◽  
Simon Griffin ◽  
Søren Brage ◽  
Nick Wareham ◽  
...  
PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0242782
Author(s):  
In Cheol Hwang ◽  
Kyoung Kon Kim ◽  
Kyu Rae Lee

Cryolipolysis has been considered as a noninvasive alternative to surgical procedures for reducing subcutaneous fat without affecting the surrounding tissues. However, no clinical trial has investigated changes in the abdominal fat tissue by 12 weeks after cryolipolysis. Therefore, in this split-body trial, we explored whether a single session of unilateral cryolipolysis could change visceral and subcutaneous adipose tissue over a period of 12 weeks. We compared the cross-sectional areas of the abdominal adipose tissue of 15 subjects (9 women; 38.3 [10.8] years) by computed tomography before and at 12 weeks after a single treatment of cryolipolysis to the left abdomen and used the right abdomen as untreated control. In addition, we measured participants’ waist circumference, percentage of body fat (by bioelectrical impedance analysis) at baseline and at 6- and 12-weeks post-treatment. Single unilateral cryolipolysis tended to reduce the cross-sectional areas of visceral adipose tissue, by 8.4 cm2 (9.9%), the waist circumferences, and the percent body fat, by 2.8 cm2 (0.6%), overall. The cross-sectional area of visceral adipose tissues on the treated side significantly decreased, by 6.8 cm2 (15.6%; P = 0.003), and that of the untreated side tended to decrease by 1.2 cm2 (3.6%). Thus, a single unilateral session of noninvasive selective cryolipolysis can be considered as a safe and effective treatment for reduction of visceral adipose tissue over a period of 12 weeks, which should result in metabolic improvement.


Obesity ◽  
2013 ◽  
Vol 21 (11) ◽  
pp. 2264-2271 ◽  
Author(s):  
Diana M. Thomas ◽  
Carl Bredlau ◽  
Anja Bosy-Westphal ◽  
Manfred Mueller ◽  
Wei Shen ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Todd Hulgan ◽  
M. Sean Boger ◽  
Diana H. Liao ◽  
Grace A. McComsey ◽  
Christine A. Wanke ◽  
...  

Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects. We assessed urinary F2-isoprostanes (F2-IsoPs), prostaglandin E2(PGE-M), prostacyclin (PGI-M), and thromboxane B2(TxB2) in HIV-infected women switching to RAL-containing antiretroviral therapy (ART). Thirty-seven women (RAL = 17; PI/NNRTI = 20) with a median age of 43 years and BMI 32 kg/m2completed week 24. TxB2increased in the RAL versus PI/NNRTI arm (+0.09 versus −0.02;P=0.06). Baseline PGI-M was lower in the RAL arm (P=0.005); no other between-arm cross-sectional differences were observed. In the PI/NNRTI arm, 24-week visceral adipose tissue change correlated with PGI-M (rho=0.45;P=0.04) and TxB2(rho=0.44;P=0.005) changes, with a trend seen for PGE-M (rho=0.41;P=0.07). In an adjusted model, age ≥ 50 years (N=8) was associated with increased PGE-M(P=0.04). In this randomized trial, a switch to RAL did not significantly affect urinary eicosanoids over 24 weeks. In women continuing PI/NNRTI, increased visceral adipose tissue correlated with increased PGI-M and PGE-M. Older age (≥50) was associated with increased PGE-M. Relationships between aging, adiposity, ART, and eicosanoids during HIV-infection require further study.


Diabetes Care ◽  
1999 ◽  
Vol 22 (9) ◽  
pp. 1471-1478 ◽  
Author(s):  
A. Pascot ◽  
S. Lemieux ◽  
I. Lemieux ◽  
D. Prud'homme ◽  
A. Tremblay ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document